FCoV-23 Biobank
This biobanking core will provide support to the overall FCoV-23 Center of Excellence for sample collection in Cyprus, archiving, and storage. Subject to shipping considerations (especially for international transport and...
Displaying 1 - 7 of 89 Results
Characterization and Interventions of a Recent Outbreak of Novel FIP
The FCoV-23 Genomic Surveillance Core will be a global rapid response resource for feline practitioners and researchers to distinguish FCoV-23 from other alpha coronaviruses. We will work with FCoV-23 Center...
Evaluation of EIDD-1931 and GS-441524 in the treatment of FCoV-23 and traditional forms of Feline Infections Peritonitis
In Cyprus, legally available drugs include EIDD-1931 (active break-down product of anti-viral Molnupiravir), and GS-441524 (active break-down product of anti-viral Remdesivir). These drugs have not been through rigorous licensing, but...
Evaluating the presence and protective nature of neutralizing antibodies against FCoV-23 in the feline population of Cyprus
The research team will develop a test to evaluate if cats have protective antibodies against FCoV-23 and if different levels of antibodies influence the types of clinical signs shown and...
Development of a patient-side serological test to distinguish FCoV-1, FCoV-2, FCov-23
FCoV-23 is a newly identified feline coronavirus associated with a large and uncontrolled outbreak of feline infectious peritonitis (FIP). A patient-side test is needed to screen cats for exposure to...
Development of differential and point of care diagnostics for FCoV-23
In this project, the team is aiming to develop two types of tests, one that can identify the genetic makeup of FCoV-23 to differentiate it from other FCoV types and...
Virus-like particles as a means to evaluate FCoV-23 cell tropism and entry pathways and spike antigenicity
This project will analyze FCoV-23, the newly emerging virus affecting cats in Cyprus. The team will assess basic aspects of the biology of this novel and highly concerning virus, and...